RTTNews BiotechCodex · 实盘不做把握 8/10
北京时间·🕒 发布 23:41:15时区推断·⟳ 抓取 23:45:24·⚡ 决策 07-28 23:45:51 +27s·90.8 天前
GSK计划三年投资4亿英镑在剑桥建设全球研发中心
该事件是GSK既有研发投入与园区搬迁升级安排，未披露新增订单、收入、利润或管线临床里程碑。
📄 原文RTTNews Biotech↗ 原文
GSK To Invest �400M In New Flagship R&D Centre In Cambridge, UK
GSK plc (GSK) announced plans to build a new global R&D centre on the Cambridge Biomedical Campus, reinforcing its comm…
不做 GSK（GSK.US）
研发中心投资和园区搬迁属于长期经营配置，金额相对年度研发支出不构成短线收入或利润增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 medium ↗
关键理由
- 该事件是GSK既有研发投入与园区搬迁升级安排，未披露新增订单、收入、利润或管线临床里程碑。
- 4亿英镑为三年资本投入，相对公司每年超过60亿英镑研发支出只是设施配置变化，不构成短周期业绩催化。
主要风险
- 若后续披露具体管线突破、重大合作或补贴资金，需按新事件重新评估。
原文全文
展开原文 · 1,590 字
GSK plc (GSK) announced plans to build a new global R&D centre on the Cambridge Biomedical Campus, reinforcing its commitment to UK life sciences with a £400 million investment over three years.
The 300,000 square-foot site will house more than 1,000 scientists and serve as GSK's UK R&D hub, providing direct access to one of Europe's largest biomedical ecosystems. The centre will feature state-of-the-art labs supporting research in oncology, respiratory, hepatology, vaccines and HIV.
CEO Luke Miels said the move will accelerate GSK's pipeline and integrate the company further into Cambridge's world-class research environment, while Chief Scientific Officer, Tony Wood, described the campus as a catalyst for faster medicines discovery.
As part of the transition, GSK will vacate its Stevenage R&D site by 2029, upgrade laboratories in Ware, and retain its global headquarters in London. The company invests over £6 billion annually in R&D, with more than £1.5 billion in the UK.
GSK has traded between $36.75 and $61.70 over the past year. The stock is currently trading at $53.96, up 3.79%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 25, 2026 02:46 ET The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
The 300,000 square-foot site will house more than 1,000 scientists and serve as GSK's UK R&D hub, providing direct access to one of Europe's largest biomedical ecosystems. The centre will feature state-of-the-art labs supporting research in oncology, respiratory, hepatology, vaccines and HIV.
CEO Luke Miels said the move will accelerate GSK's pipeline and integrate the company further into Cambridge's world-class research environment, while Chief Scientific Officer, Tony Wood, described the campus as a catalyst for faster medicines discovery.
As part of the transition, GSK will vacate its Stevenage R&D site by 2029, upgrade laboratories in Ware, and retain its global headquarters in London. The company invests over £6 billion annually in R&D, with more than £1.5 billion in the UK.
GSK has traded between $36.75 and $61.70 over the past year. The stock is currently trading at $53.96, up 3.79%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 25, 2026 02:46 ET The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。